# US 2025/0082730 A1 · Treatment of post-bariatric hypoglycemia with exendin (9-39)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082730 A1
- Document ID: US20250082730A1
- Status: Published application
- Kind: A1
- Application number: 18/745,091
- Filed: 2024-06-17
- Published: 2025-03-13
- Earliest claimed: 2015-05-22
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Tracey L. MCLAUGHLIN; Colleen M. CRAIG
- Web page: https://patentgrep.com/patent/US20250082730A1

## CPC

- A61K 38/2278: {Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 38/26: Glucagons
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.

## Claims

### Claim 1

A method for treating or preventing hyperinsulinemic hypoglycemia in a patient, the method comprising subcutaneous administration of a composition comprising a therapeutically effective amount of exendin(9-39), wherein the composition is administered in a volume of 0.25 mL to 2 mL.

### Claim at position 2

2-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein administration results in a steady state plasma exendin(9-39) concentration of at least 100 ng/ml as measured by liquid chromatograph-mass spectrometry.

### Claim at position 4

11-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the composition is administered before the morning meal.

### Claim 14 (depends on 1)

The method of claim 1, wherein the composition is administered at least 1 hour before the morning meal.

### Claim at position 7

15-31. (canceled)

### Claim 32 (depends on 1)

The method of claim 1, wherein the exendin(9-39) is administered once per day.

### Claim 33 (depends on 1)

The method of claim 1, wherein the patient has previously had bariatric surgery.

### Claim 34 (depends on 32)

The method of claim 32, wherein the bariatric surgery is Roux-en-Y gastric bypass, vertical sleeve gastrectomy, placement of an endosleeve device, duodenal mucosal resurfacing, partial bypass of the duodenum, vagal nerve blockade, or pyloroplasty.

### Claim 35 (depends on 1)

The method of claim 1, wherein the patient has previously had gastrointestinal surgery.

### Claim 36 (depends on 35)

The method of claim 35, wherein the gastrointestinal surgery is gastrectomy, Nissen Fundoplication, or esophagectomy.

### Claim 37 (depends on 1)

The method of claim 1, wherein the composition is an isotonic solution.

### Claim 38 (depends on 1)

The method of claim 1, wherein the composition is administered using a pen injector.

### Claim 39 (depends on 1)

The method of claim 1, wherein the composition comprises at least one of an antimicrobial preservative, a tonicity adjusting agent, or a buffer.

### Claim 40 (depends on 1)

The method of claim 1, further comprising, prior to administering:
providing the exendin(9-39) in lyophilized form; and
solubilizing the lyophilized form of the exendin(9-39) to form the composition.
